503605-66-1
503605-66-1 structure
- Name: Adecatumumab
- Chemical Name: Adecatumumab
- CAS Number: 503605-66-1
- Molecular Formula:
- Molecular Weight: 147.5 (kDa)
- Catalog: Research Areas Cancer
- Create Date: 2023-01-11 22:39:44
- Modify Date: 2025-11-25 16:52:05
-
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status[1][2].
| Name | Adecatumumab |
|---|
| Description | Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Human EPCAM[1] |
| In Vitro | Adecatumumab (4 μM; 18 h) shows diverse kinetic binding activities among human Adecatumumab and murine Adecatumumab in B16/EpCAM 3E3 cells[2]. Adecatumumab (0.1 ng/mL-0.1 mg/mL; 4 h) shows a dose-dependent Antibodies depend on cell-mediated cytotoxicity (ADCC) activity in natural killing (NK) cells[2]. |
| In Vivo | Adecatumumab (300 μg/mouse; i.v. bolus injection; 3 times per week) inhibits tumor growth in B16/EpCAM xenograft tumor model in mice, both of human adecatumumab and mu-adecatumumab[2]. Both human adecatumumab and mu-adecatumumab (300 μg/mouse; i.v. bolus injection; single dose) exhibit a bi-exponential curve progression of serum concentration with an early distribution phase between 0 and 10 h and a terminal elimination phase[2]. Animal Model: Female immunocompetent C57BL/6 mice (6-10 weeks old) with B16/EpCAM (i.v.)[2] Dosage: 250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab Administration: 250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab Result: Both of them exhibited anti-tumor activity against B16/EpCAM cells in mice. Although human adecatumumab inhibited the size of tumor colonies mice, the number of colonies was only slightly reduced after treatment without significant difference. In contrast, mu-adecatumumab induced a highly significant reduction in the number of lung tumor colonies by >85%, and the few remaining tumor colonies were of very small size. |
| References |
| Molecular Weight | 147.5 (kDa) |
|---|